Monument Capital Management Has $644,000 Stake in Amgen Inc. (NASDAQ:AMGN)

Monument Capital Management lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 3.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,236 shares of the medical research company’s stock after acquiring an additional 66 shares during the quarter. Monument Capital Management’s holdings in Amgen were worth $644,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of AMGN. Southland Equity Partners LLC increased its holdings in Amgen by 2.3% in the fourth quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock valued at $443,000 after purchasing an additional 34 shares during the period. Acropolis Investment Management LLC increased its holdings in Amgen by 3.5% in the fourth quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company’s stock valued at $288,000 after purchasing an additional 34 shares during the period. Opal Wealth Advisors LLC increased its holdings in Amgen by 1.9% in the fourth quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company’s stock valued at $538,000 after purchasing an additional 34 shares during the period. Marino Stram & Associates LLC increased its holdings in Amgen by 0.7% in the fourth quarter. Marino Stram & Associates LLC now owns 4,626 shares of the medical research company’s stock valued at $1,332,000 after purchasing an additional 34 shares during the period. Finally, FORVIS Wealth Advisors LLC grew its holdings in Amgen by 1.4% during the 4th quarter. FORVIS Wealth Advisors LLC now owns 2,578 shares of the medical research company’s stock worth $743,000 after acquiring an additional 35 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on AMGN shares. Raymond James started coverage on Amgen in a report on Thursday, March 28th. They set a “market perform” rating for the company. UBS Group decreased their price target on Amgen from $314.00 to $284.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Morgan Stanley decreased their price target on Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a report on Wednesday, February 7th. The Goldman Sachs Group increased their price target on Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th. Finally, SVB Leerink downgraded Amgen from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $324.00 to $318.00 in a report on Wednesday, February 7th. Ten analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $296.95.

Amgen Trading Up 1.1 %

Shares of AMGN stock opened at $271.91 on Tuesday. The company’s fifty day simple moving average is $276.45 and its two-hundred day simple moving average is $281.56. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. Amgen Inc. has a 1 year low of $211.71 and a 1 year high of $329.72. The stock has a market capitalization of $145.85 billion, a price-to-earnings ratio of 21.77, a PEG ratio of 2.50 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. The firm had revenue of $8.20 billion during the quarter, compared to analyst estimates of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same period in the previous year, the business earned $4.09 EPS. As a group, analysts anticipate that Amgen Inc. will post 19.45 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be given a $2.25 dividend. The ex-dividend date is Thursday, May 16th. This represents a $9.00 annualized dividend and a yield of 3.31%. Amgen’s dividend payout ratio (DPR) is presently 72.06%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.